USPTO Examiner SAEED KAMAL A - Art Unit 1626

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19312645CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITORAugust 2025January 2026Allow410NoNo
19312755CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITORAugust 2025January 2026Allow410NoNo
19312786CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITORAugust 2025January 2026Allow410NoNo
19313046CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITORAugust 2025February 2026Allow610NoNo
19313010CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITORAugust 2025February 2026Allow610NoNo
19312656CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITORAugust 2025December 2025Allow300NoNo
19238613METHOD FOR FORMING AN N-SUBSTITUTED PYRROLE FROM A HEXADIONE WITH A JUICE CATALYSTJune 2025August 2025Allow210NoNo
19225802NON-COVALENT MODIFIERS OF AKT1 AND USES THEREOFJune 2025December 2025Allow610YesNo
192159387-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAMEMay 2025August 2025Allow310NoNo
19187874JUICE-BASED SYNTHETIC METHOD FOR PYRROLESApril 2025July 2025Allow310NoNo
19187847PYRROLE SYNTHESIS METHOD USING JUICE CATALYSTApril 2025July 2025Allow310NoNo
19187833GREEN SYNTHESIS METHOD FOR FORMING SUBSTITUTED PYRROLESApril 2025June 2025Allow200YesNo
19187339SYNTHESIS OF N-SUBSTITUTED PYRROLES BY GREEN CATALYSTApril 2025June 2025Allow200YesNo
19041219CCR5 INHIBITORJanuary 2025May 2025Allow310NoNo
19003381ORGANOSELENIUM BENZIMIDAZOLE COMPOUNDS FOR TREATING CANCERDecember 2024March 2025Allow200NoNo
18973849LEFLUTROZOLE COMPOSITIONS OF MATTER AND PROCESSES FOR PREPARATIONDecember 2024March 2025Allow300NoNo
18968441MIXED SEROTONIN 5-HT2A/2C RECEPTOR AGONISTS AND METHODS FOR TREATING PAIN AND DEPRESSIONDecember 2024March 2025Allow311NoNo
18939592CYTOTOXIC TREATMENT OF CANCER CELLSNovember 2024January 2025Allow210NoNo
18799676METHOD FOR CONTACTING CANCER CELLS WITH ANTITUMOR AGENT AND APOPTOTIC INDUCERAugust 2024October 2024Allow210NoNo
18748709TREATMENT OF COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIAJune 2024September 2025Abandon1501NoNo
18745664PARP INHIBITORS FOR TREATING CANCER AND ASTHMAJune 2024April 2025Allow1010YesNo
18741888Neuroplastogens and Non-Hallucinogenic Serotonin 5-HT2A Receptor ModulatorsJune 2024December 2024Allow610NoNo
18731154CFTR REGULATORS AND METHODS OF USE THEREOFMay 2024April 2025Allow1000NoNo
18671182PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORSMay 2024December 2024Allow600NoNo
186613373-(2-(1,3-DIOXOISOINDOLIN-2-YL)ETHYL)-5-(2-HYDROXY-5-NITROBENZYLIDENE)THIAZOLIDINE-2,4-DIONE AS A POTENTIAL ANTITUMOR AND APOPTOTIC INDUCERMay 2024July 2024Allow200NoNo
18659338PROCESSES FOR THE PREPARATION OF 4-{8-AMINO-3-[(2S)-1-(BUT-2-YNOYL)-PYRROLIDIN-2-YL]IMIDAZO[1,5-a]-PYRAZIN-1-YL}N-(PYRIDIN-2-YL)-BENZAMIDEMay 2024July 2025Allow1401NoNo
18656222NEUROPROTECTIVE COMPOSITIONS AND METHODS OF USING THE SAMEMay 2024February 2026Allow2111NoNo
18636634Prodigiosin Analogs And Methods Of UseApril 2024February 2025Allow1010YesNo
18622657PROCESSES FOR PREPARING SOLID STATE FORMSMarch 2024March 2025Allow1121NoNo
18605379THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOFMarch 2024March 2025Allow1201YesNo
18594979SUBSTITUTED PYRROLIDONES AND PIPERIDONES AS SMALL MOLECULE INHIBITORS OF EZH2 AND EED PROTEIN BINDINGMarch 2024December 2025Allow2111NoNo
18590133THIAZOLE TETHERED ORGANOSELENIDES AS 5-LIPOXYGENASE INHIBITORSFebruary 2024April 2024Allow200NoNo
18442885CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOFFebruary 2024February 2025Allow1210NoNo
18435082SOLID DOSAGE FORM HAVING EXCELLENT STABILITYFebruary 2024June 2025Allow1610NoNo
18427639MODULATORS OF KV3 CHANNELS TO TREAT PAINJanuary 2024December 2025Abandon2320NoNo
18422118TINOSTAMUSTINE FOR USE IN THE TREATMENT OF T-CELL PROLYMPHOCYTIC LEUKAEMIAJanuary 2024March 2025Allow1410NoNo
18402493BIPYRAZOLE DERIVATIVES AS JAK INHIBITORSJanuary 2024November 2024Allow1010NoNo
183959923-(4-CHLOROPHENYL)-5-{[5-METHYL-2-(PROPAN-2-YL)PHENOXY]METHYL}- 1,2,4-OXADIAZOLE AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUNDDecember 2023April 2024Allow400NoNo
183962433-(4-CHLOROPHENYL)-5-{[5-METHYL-2-(PROPAN-2-YL)PHENOXY]METHYL}- 1,2,4-OXADIAZOLE AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUNDDecember 2023March 2024Allow200NoNo
18394624COMPOUNDSDecember 2023March 2025Abandon1501NoNo
18573305AZETIDINYL PYRIMIDINES AND USES THEREOFDecember 2023March 2026Allow2700YesNo
18390780COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL CONDITIONSDecember 2023August 2024Allow811NoNo
18545558SULCARDINE ADMINISTRATION FOR TREATMENT OF ACUTE ATRIAL FIBRILLATIONDecember 2023November 2024Allow1110NoNo
18545458SUBSTITUTED 2-AMINOBENZIMIDAZOLES ANALOGS AS ANTIBIOFILM AGENTSDecember 2023April 2025Allow1610NoNo
18544963DIALKYL TRYPTAMINES AND THEIR THERAPEUTIC USESDecember 2023September 2025Abandon2101NoNo
18539688PHARMACEUTICAL INTERMEDIATES AND METHODS FOR PREPARING THE SAME IN THE SYNTHESIS OF MUSCIMOL AND CONGENERS AND DERIVATIVES THEREOFDecember 2023April 2024Allow411NoNo
18536542Neuroplastogens and Non-Hallucinogenic Serotonin 5-HT2A Receptor ModulatorsDecember 2023April 2024Allow410YesNo
18531575PYRIMIDINE AND PYRIDINE AMINE COMPOUNDS AND USAGE THEREOF IN DISEASE TREATMENTDecember 2023September 2024Allow900NoNo
18516458DUAL INHIBITORS OF TIM-3 AND PD-1 PATHWAYSNovember 2023October 2024Allow1110NoNo
18516358INHIBITION OF DIPEPTIDE REPEAT PROTEINSNovember 2023January 2025Allow1410NoNo
18561835SYNTHESIS OF N-VINYL COMPOUNDS BY REACTING NH-COMPOUNDS WITH ACETYLENE IN PRESENCE OF HOMOGENEOUS PHOSPHINE CATALYSTNovember 2023June 2024Allow700NoNo
18481141AUTOTAXIN INHIBITOR COMPOUNDSOctober 2023December 2024Allow1410NoNo
18474522PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALOPECIA AREATA ACTING AS A FUNCTIONAL ANTAGONIST FOR S1PR1 AND S1PR4September 2023February 2024Allow510YesNo
18468636PROCESS FOR PREPARING AFICAMTENSeptember 2023November 2024Allow1410NoNo
18368143CRYSTALLINE SALTS OF N-ETHYL-(5-FLUORO-1H-INDOL-3-YL)-N-METHYLETHAN-1-AMINESeptember 2023February 2024Allow502YesNo
18459944BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTORSeptember 2023August 2025Abandon2411NoNo
182387133-(4-CHLOROPHENYL)-5-{[5-METHYL-2-(PROPAN-2-YL)PHENOXY]METHYL}- 1,2,4-OXADIAZOLE AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUNDAugust 2023November 2023Allow201NoNo
18453887PYRROLE COMPOUNDSAugust 2023November 2025Allow2611YesNo
18451757BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOFAugust 2023March 2025Abandon1920NoNo
18448495METHODS OF INHIBITING TUMOR METASTASISAugust 2023March 2025Abandon1901NoNo
18362249COMPOUNDS USEFUL AS KINASE INHIBITORSJuly 2023September 2024Allow1310NoNo
18360976METHODS OF TREATING PSYCHOLOGICAL DISORDERS THROUGH THE ADMINISTRATION OF SEROTONIN 5-HT2C RECEPTOR MODULATORSJuly 2023August 2024Allow1310NoNo
18274093PYRAZOLAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOFJuly 2023March 2026Allow3100NoNo
18354848XANTHOHUMOL DERIVATIVES AND METHODS FOR MAKING AND USINGJuly 2023October 2025Allow2700NoNo
18223169THERAPEUTIC COMPOUNDSJuly 2023November 2024Abandon1610NoNo
18353492DEUTERATED TRYPTAMINE DERIVATIVES AND METHODS OF USEJuly 2023June 2024Allow1110NoNo
18352721TREATING PRIMARY OR IDIOPATHIC HYPEROXALURIA WITH SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASEJuly 2023October 2024Allow1510YesNo
18343415METHYLLACTAM RING COMPOUND AND PHARMACEUTICAL USE THEREOFJune 2023April 2025Allow2101NoNo
18258586MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOFJune 2023September 2025Allow2700NoNo
18337313MCT4 INHIBITORS FOR TREATING DISEASEJune 2023August 2024Allow1410NoNo
18257746MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOFJune 2023September 2025Allow2700YesNo
18210330PROCESS FOR THE PRODUCTION OF LEVETIRACETAMJune 2023November 2025Allow2900YesNo
18208633PROCESS FOR THE PRODUCTION OF LEVETIRACETAM AND INTERMEDIATES THEREOFJune 2023September 2025Allow2800NoNo
18207447RADIATION MITIGATOR AND METHOD OF USE THEREOFJune 2023November 2024Allow1710YesNo
18331779PYRAZOLE COMPOUNDS SUBSTITUTED WITH HETEROARYL AND PHARMACEUTICAL USE THEREOFJune 2023January 2026Allow3121NoNo
18256570DIALKYL TRYPTAMINES AND THEIR THERAPEUTIC USESJune 2023February 2025Allow2121NoNo
18201715INHIBITORS OF VAP-1May 2023September 2024Allow1611NoNo
18197615NEW FORMULATIONSMay 2023July 2024Allow1410NoNo
18316183CFTR REGULATORS AND METHODS OF USE THEREOFMay 2023March 2024Allow1010NoNo
18140966NOVEL PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORSApril 2023February 2024Allow1010NoNo
18306652BENZOSELENOPHENE, BENZOTHIOPHENE, AND BENZOFURAN ANALOGS AND METHODS OF MODULATING THE SEROTONIN 5-HT2C RECEPTORApril 2023July 2023Allow300NoNo
18136016HUMAN PLASMA KALLIKREIN INHIBITORSApril 2023July 2024Allow1510NoNo
18136025HUMAN PLASMA KALLIKREIN INHIBITORSApril 2023June 2024Allow1410NoNo
18194609CATHEPSIN L INHIBITORSMarch 2023September 2023Allow610NoNo
18128850REMDESIVIR TREATMENT METHODSMarch 2023September 2023Allow610NoNo
18246074NOVEL POTASSIUM CHANNEL INHIBITORSMarch 2023August 2025Allow2900NoNo
18120073CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITORMarch 2023January 2025Abandon2210NoNo
18173573NEPRILYSIN INHIBITORSFebruary 2023October 2023Allow800NoNo
18112790SILOXANE DERIVATIVES OF AMINO ACIDS HAVING SURFACE-ACTIVE PROPERTIESFebruary 2023August 2025Allow2900NoNo
18166789INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO)February 2023December 2023Allow1010NoNo
18165037COMPOUNDS USEFUL FOR INHIBITING RET KINASEFebruary 2023December 2023Allow1010NoNo
18162398METHODS AND COMPOSITIONS FOR TOPICAL DELIVERY OF PROSTAGLANDINS TO SUBCUTANEOUS FATJanuary 2023February 2024Abandon1310NoNo
18160060DEUTERATED COMPOUNDS FOR RESTORING MUTANT p53 FUNCTIONJanuary 2023January 2024Allow1210NoNo
18006856COMPOSITIONS ND METHODS USING SAME FOR GERMANIUM SEED LAYERJanuary 2023September 2025Allow3110YesNo
18101014BIPYRAZOLE DERIVATIVES AS JAK INHIBITORSJanuary 2023October 2023Allow910NoNo
18017449METHOD FOR PRODUCING A-HYDROXY CARBOXYLIC ACID COMPOSITIONJanuary 2023November 2025Allow3410NoNo
18155924COMPOUND HAVING OXADIAZOLE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAMEJanuary 2023July 2024Allow1820NoNo
18097814NAPHTHALENE ISOXAZOLINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTSJanuary 2023July 2024Allow1821NoNo
18154894COMPLEX OF GADOLINIUM AND A CHELATING LIGAND DERIVED FROM A DIASTEREOISOMERICALLY ENRICHED PCTA AND PREPARATION AND PURIFICATION PROCESSJanuary 2023April 2024Allow1520YesNo
18153319Sphingosine Pathway Modulating Compounds For The Treatment Of Coronavirus InfectionJanuary 2023November 2023Allow1010YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SAEED, KAMAL A.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
1
Examiner Affirmed
1
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
0.3%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
15
Allowed After Appeal Filing
6
(40.0%)
Not Allowed After Appeal Filing
9
(60.0%)
Filing Benefit Percentile
64.9%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 40.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner SAEED, KAMAL A - Prosecution Strategy Guide

Executive Summary

Examiner SAEED, KAMAL A works in Art Unit 1626 and has examined 2,607 patent applications in our dataset. With an allowance rate of 85.2%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 21 months.

Allowance Patterns

Examiner SAEED, KAMAL A's allowance rate of 85.2% places them in the 61% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.

Office Action Patterns

On average, applications examined by SAEED, KAMAL A receive 0.77 office actions before reaching final disposition. This places the examiner in the 5% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SAEED, KAMAL A is 21 months. This places the examiner in the 90% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +3.8% benefit to allowance rate for applications examined by SAEED, KAMAL A. This interview benefit is in the 27% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 45.6% of applications are subsequently allowed. This success rate is in the 96% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 81.0% of cases where such amendments are filed. This entry rate is in the 96% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 92.3% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 83.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 50.8% are granted (fully or in part). This grant rate is in the 50% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 15.4% of allowed cases (in the 97% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.8% of allowed cases (in the 82% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.